H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Aprea Therapeutics (APRE - Research Report) and set a price target of $3.00.
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on developing and commercializing novel cancer therapeutics that reactivate mutant protein 53 (p53) tumor suppressor protein. The Company's lead product candidate, APR-246, or eprenetapopt, is a small molecule p53 reactivator that is in clinical development for hematologic malignancies, including myelodysplastic syndromes, or myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). The Company's APR-548 is a second generation p53 reactivator that is a unique analog of eprenetapopt and therefore a pro-drug of MQ. APR-548 exhibits high oral bioavailability in preclinical testing and is being developed in an oral dosage form. The Company has initiated a Phase I clinical trial testing APR-548 in relapsed/refractory MDS and AML. Its solid tumor program includes its clinical trial evaluating eprenetapopt with anti-PD-1 therapy in advanced solid tumors.
Total Cash (mrq) 33.11M Total Cash Per Share (mrq) 0.62 Total Debt (mrq) 110.55k Shares Outstanding 53M % Held by Insiders 24.17%
Sep 30, 2022 0.8380 Jun 30, 2022 1.2900 Apr 30, 2022 1.5500 Mar 31, 2022 2.0400 Jan 01, 2022 3.2100 Dec 01, 2021 4.7000 Sep 30, 2021 5.6700 May 31, 2021 7.8000 Dec 01, 2020 30.9910
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.